GlassScriptPhysician profile
Niall Roche
NPI 1194755918
$9,249.79
in general payments reported to CMS, 2019-2025
12 companies · $1,298 in 2025
The $1,298 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,023 · 2020: $614 · 2021: $732 · 2022: $798 · 2023: $1,094 · 2024: $3,691 · 2025: $1,298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,867 · Consulting Fee: $2,160 · Education: $54.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,867.25 |
| Consulting Fee | $2,160.00 |
| Education | $54.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $5,682.15 | 2020-2025 | Tremfya, Simponi Aria |
| Amgen INC. | $1,530.13 | 2019-2025 | Enbrel, Tavneos, Otezla |
| Novartis Pharmaceuticals Corporation | $724.44 | 2019-2025 | |
| Abbvie INC. | $705.30 | 2019-2025 | Rinvoq |
| Ucb, INC. | $266.27 | 2024-2025 | Cimzia, Bimzelx |
| Pfizer INC. | $112.98 | 2019-2023 | |
| Fresenius Kabi USA, LLC | $75.53 | 2023 | Idacio |
| Horizon Therapeutics Plc | $56.28 | 2022-2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.34 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $24.31 | 2019 | |
| Alexion Pharmaceuticals, INC. | $22.70 | 2023 | Strensiq |
| Celgene Corporation | $20.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Niall Roche listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.